Book chapter
Anti-PD-1 and Anti-PD-L1 mAbs
Immunotherapy of Cancer, pp.283-294
Springer Japan
02/23/2016
DOI: 10.1007/978-4-431-55031-0_19
Abstract
Programmed death-1 (PD-1) is a co-receptor molecule expressed on immune effector cells and plays a pivotal role in the down-modulation of the immune system. Upon engagement with PD-L1 or PD-L2 ligands, PD-1 delivers an inhibitory signal to immune effector cells. In animal models, the blockade of the PD-1/PD-L1 checkpoint by anti-PD-1 or anti-PD-L1 monoclonal antibodies (mAbs) is an effective strategy for reversing immunosuppression of effector T cells significantly enhancing tumor immunity in vivo. In humans, the expression of PD-1 ligands on tumor cells has been shown to correlate with poor prognosis in a wide spectrum of tumors. More recently, clinical trials have been carried out to examine the effect of inhibiting the PD-1/PD-L1 checkpoint in patients with advanced tumors. Blocking either PD-1 or PD-L1 with specific mAbs effectively treats patients with a variety of cancers including melanoma, renal cell carcinoma, non-small-cell lung cancer, and others, in some cases inducing durable remissions. Although their use is still under study to determine which cancers respond to treatment and which mAb combinations might be the most effective, blocking mAbs specific for the PD-1/PD-L1 immune checkpoint promise to revolutionize cancer therapy.
Details
- Title: Subtitle
- Anti-PD-1 and Anti-PD-L1 mAbs
- Creators
- Yoshimasa Tanaka - Nagasaki UniversityCraig T. Morita - University of IowaHaruki Okamura - Hyogo Medical University
- Resource Type
- Book chapter
- Publication Details
- Immunotherapy of Cancer, pp.283-294
- Publisher
- Springer Japan; Tokyo
- DOI
- 10.1007/978-4-431-55031-0_19
- Language
- English
- Date published
- 02/23/2016
- Academic Unit
- Immunology; Internal Medicine
- Record Identifier
- 9984360145102771
Metrics
7 Record Views